BRYN MAWR TRUST Co Decreases Stake in Bristol-Myers Squibb (NYSE:BMY)

BRYN MAWR TRUST Co lowered its position in Bristol-Myers Squibb (NYSE:BMYGet Rating) by 7.7% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 105,026 shares of the biopharmaceutical company’s stock after selling 8,730 shares during the period. BRYN MAWR TRUST Co’s holdings in Bristol-Myers Squibb were worth $6,548,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Wellington Management Group LLP raised its holdings in shares of Bristol-Myers Squibb by 3.3% during the 3rd quarter. Wellington Management Group LLP now owns 45,407,364 shares of the biopharmaceutical company’s stock worth $2,686,754,000 after acquiring an additional 1,444,304 shares during the period. Geode Capital Management LLC raised its holdings in shares of Bristol-Myers Squibb by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 36,940,288 shares of the biopharmaceutical company’s stock worth $2,179,937,000 after acquiring an additional 982,470 shares during the period. Nordea Investment Management AB raised its holdings in shares of Bristol-Myers Squibb by 20.8% during the 4th quarter. Nordea Investment Management AB now owns 18,130,455 shares of the biopharmaceutical company’s stock worth $1,136,598,000 after acquiring an additional 3,124,811 shares during the period. Invesco Ltd. raised its holdings in shares of Bristol-Myers Squibb by 2.2% during the 3rd quarter. Invesco Ltd. now owns 15,731,092 shares of the biopharmaceutical company’s stock worth $930,809,000 after acquiring an additional 331,205 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Bristol-Myers Squibb by 9.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 12,808,859 shares of the biopharmaceutical company’s stock worth $798,646,000 after acquiring an additional 1,130,892 shares during the period. Institutional investors and hedge funds own 73.07% of the company’s stock.

Shares of Bristol-Myers Squibb stock traded down $0.50 on Friday, reaching $75.80. 13,773,108 shares of the company were exchanged, compared to its average volume of 14,853,342. Bristol-Myers Squibb has a 1-year low of $53.22 and a 1-year high of $78.17. The company has a market cap of $161.38 billion, a P/E ratio of 26.88, a price-to-earnings-growth ratio of 1.61 and a beta of 0.49. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.32 and a quick ratio of 1.23. The stock’s 50 day moving average price is $74.15 and its 200-day moving average price is $66.36.

Bristol-Myers Squibb (NYSE:BMYGet Rating) last announced its quarterly earnings data on Friday, April 29th. The biopharmaceutical company reported $1.96 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.05. Bristol-Myers Squibb had a return on equity of 48.37% and a net margin of 13.31%. The business had revenue of $11.65 billion during the quarter, compared to the consensus estimate of $11.34 billion. During the same period in the previous year, the company posted $1.74 earnings per share. The business’s revenue for the quarter was up 5.2% on a year-over-year basis. On average, research analysts predict that Bristol-Myers Squibb will post 7.57 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Monday, May 2nd. Stockholders of record on Friday, April 1st were given a dividend of $0.54 per share. This represents a $2.16 dividend on an annualized basis and a dividend yield of 2.85%. The ex-dividend date was Thursday, March 31st. Bristol-Myers Squibb’s dividend payout ratio is presently 76.60%.

In related news, EVP Rupert Vessey sold 74,559 shares of the business’s stock in a transaction that occurred on Wednesday, March 16th. The stock was sold at an average price of $69.25, for a total transaction of $5,163,210.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Giovanni Caforio sold 30,000 shares of the business’s stock in a transaction that occurred on Thursday, February 24th. The stock was sold at an average price of $67.00, for a total value of $2,010,000.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 165,668 shares of company stock valued at $11,459,888. Corporate insiders own 0.09% of the company’s stock.

A number of brokerages recently issued reports on BMY. Wells Fargo & Company raised their price objective on Bristol-Myers Squibb from $60.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Wednesday, March 2nd. Morgan Stanley cut their price objective on Bristol-Myers Squibb from $66.00 to $64.00 and set an “underweight” rating for the company in a research report on Wednesday, April 6th. Truist Financial raised their price objective on Bristol-Myers Squibb from $76.00 to $81.00 in a research report on Monday, May 2nd. StockNews.com started coverage on Bristol-Myers Squibb in a research report on Thursday, March 31st. They issued a “strong-buy” rating for the company. Finally, BMO Capital Markets lifted their target price on Bristol-Myers Squibb from $87.00 to $92.00 in a research report on Monday, May 2nd. One investment analyst has rated the stock with a sell rating, three have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Bristol-Myers Squibb currently has a consensus rating of “Buy” and a consensus price target of $71.33.

Bristol-Myers Squibb Profile (Get Rating)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

Read More

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.